NASDAQ:BCLI

Brainstorm Cell Therapeutics - BCLI Stock Forecast, Price & News

$1.53

-0.04 (-2.55%)

(As of 12/7/2022 12:00 AM ET)

Add

Compare

Today's Range: $1.50
▼
$1.64
50-Day Range: $1.50
▼
$4.42
52-Week Range: $1.09
▼
$4.70

Volume: 85,991 shs
Average Volume: 141,723 shs
Market Capitalization: $55.82 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Brainstorm Cell Therapeutics MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 226.8% Upside
$5.00 Price Target
Short Interest: Bearish
9.14% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.66
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.72) to ($0.60) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

692nd out of 1,027 stocks

Biological Products, Except Diagnostic Industry

108th out of 171 stocks

3.0

Analyst's Opinion

Consensus Rating
Brainstorm Cell Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, Brainstorm Cell Therapeutics has a forecasted upside of 226.8% from its current price of $1.53.
Amount of Analyst Coverage
Brainstorm Cell Therapeutics has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
9.14% of the float of Brainstorm Cell Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Brainstorm Cell Therapeutics has a short interest ratio ("days to cover") of 9.8.
Change versus previous month
Short interest in Brainstorm Cell Therapeutics has recently decreased by 4.09%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Brainstorm Cell Therapeutics does not currently pay a dividend.
Dividend Growth
Brainstorm Cell Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Brainstorm Cell Therapeutics has received a 76.26% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for the nervous system", "Preclinical research services for physical health", and "Preclinical research services for mental health" products. See details.
Environmental Sustainability
The Environmental Impact score for Brainstorm Cell Therapeutics is -0.66.

0.6

News and Social Media Coverage

Search Interest
Only 1 people have searched for BCLI on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
MarketBeat Follows
7 people have added Brainstorm Cell Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Brainstorm Cell Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
21.04% of the stock of Brainstorm Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 10.83% of the stock of Brainstorm Cell Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Brainstorm Cell Therapeutics are expected to grow in the coming year, from ($0.72) to ($0.60) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Brainstorm Cell Therapeutics is -2.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Brainstorm Cell Therapeutics is -2.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Brainstorm Cell Therapeutics has a P/B Ratio of 2.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Receive BCLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCLI Stock News Headlines

November 14, 2022 | finance.yahoo.com

BrainStorm Cell Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Corporate Update

November 10, 2022 | finance.yahoo.com

BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the treatment of ALS

November 10, 2022 | finance.yahoo.com

FDA Refuses To Accept BrainStorm Cell's Lead Candidate For Amyotrophic Lateral Sclerosis

November 8, 2022 | finance.yahoo.com

BrainStorm Cell Therapeutics to Announce Third Quarter Results and Provide a Corporate Update

November 7, 2022 | finance.yahoo.com

BrainStorm Cell Therapeutics Presents New Analyses from NurOwn's Phase 3 ALS Trial at the 21st Annual NEALS Meeting

October 20, 2022 | finance.yahoo.com

BrainStorm Cell Therapeutics Presents NurOwn® Phase 2 Progressive MS Biomarker Data at the 38th ECTRIMS Congress

October 7, 2022 | finance.yahoo.com

BrainStorm Presents New Biomarker Analyses from NurOwn's Phase 3 ALS Trial at the ALS ONE Research Symposium

October 4, 2022 | finance.yahoo.com

BCLI: Relvyrio™ Approval Shows FDA Flexibility for ALS Treatments…

September 15, 2022 | finance.yahoo.com

BrainStorm Cell Therapeutics Announces Peer Reviewed Publication of Results from the NurOwn® Phase 2 Progressive MS Trial in Multiple Sclerosis Journal

August 17, 2022 | finance.yahoo.com

BCLI: Filing a BLA for NurOwn® for the Treatment of ALS…

August 15, 2022 | seekingalpha.com

Brainstorm Cell Therapeutics Inc.'s (BCLI) CEO Chaim Lebovits on Q2 2022 Results - Earnings Call Transcript

August 15, 2022 | seekingalpha.com

BrainStorm to seek FDA approval for ALS therapy despite Phase 3 setback

August 15, 2022 | finance.yahoo.com

BrainStorm Cell Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Corporate Update

August 10, 2022 | americanbankingnews.com

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated by Analysts at StockNews.com

August 1, 2022 | finance.yahoo.com

BrainStorm to Announce Second Quarter Results and Provide a Corporate Update

May 31, 2022 | finance.yahoo.com

BrainStorm Announces Presentations at June 2022 Scientific Conferences

May 24, 2022 | finance.yahoo.com

BCLI: Anticipating News on How NurOwn® Will be Advanced Forward…

May 16, 2022 | investing.com

Brainstorm Cell Therapeutics Misses Q1 EPS by 2c

May 16, 2022 | seekingalpha.com

BrainStorm Cell Therapeutics GAAP EPS of -$0.15 misses by $0.02

May 16, 2022 | finance.yahoo.com

BrainStorm Cell Therapeutics Announces First Quarter 2022 Financial Results and Provides a Corporate Update

May 13, 2022 | benzinga.com

Brainstorm Cell Earnings Preview

May 12, 2022 | finance.yahoo.com

BrainStorm Strengthens Executive Team with Key Appointments in R&D and Legal

May 4, 2022 | finance.yahoo.com

BrainStorm Announces Presentation of NurOwn® Exosome Preclinical Data at ISCT 2022 San Francisco Meeting

May 3, 2022 | finance.yahoo.com

BrainStorm Announces Upcoming Scientific Conference Presentations

May 2, 2022 | finance.yahoo.com

BrainStorm to Announce First Quarter 2022 Financial Results and Provide a Corporate Update

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BCLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCLI Company Calendar

Last Earnings: 11/15/2021
Today: 12/08/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/27/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BCLI
CUSIP: N/A
CIK: 1137883
Web: www.brainstorm-cell.com
Phone: (201) 488-0460
Fax: N/A
Employees: 43
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.00
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +226.8%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.70)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-24,460,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -236.36%
Return on Assets: -116.63%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.84
Quick Ratio: 0.84

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.53 per share
Price / Book: 2.89

Miscellaneous

Outstanding Shares: 36,486,000
Free Float: 28,809,000
Market Cap: $55.82 million
Optionable: Optionable
Beta: -0.44

Key Executives

Mr. Chaim Lebovits (Age 51)
Chief Exec. Officer
Comp: $1.02M

Dr. Irit Arbel DSc (Age 62)
Ph.D., Co-Founder & Independent Vice Chair of the Board

Dr. Ralph Z. Kern (Age 64)
Pres & Chief Medical Officer
Comp: $812.86k

Dr. Stacy R. Lindborg Ph.D. (Age 51)
Exec. VP & Chief Devel. Officer
Comp: $736.68k

Mr. Uri Yablonka (Age 45)
Exec. VP, Chief Bus. Officer, Sec. & Director

Ms. Alla Patlis CPA (Age 35)
M.B.A., Controller & Interim CFO

Dr. David Setboun M.B.A. (Age 47)
Pharm.D., Exec. VP & COO

Dr. Yael Gothelf
VP of Scientific & Regulatory Affairs

Ms. Antal Pearl-Lendner
VP & Chief Legal Counsel

Dr. Daniel Offen Ph.D.
Chief Scientific Advisor

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BCLI Stock - Frequently Asked Questions

Should I buy or sell Brainstorm Cell Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BCLI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BCLI, but not buy additional shares or sell existing shares.
View BCLI analyst ratings or view top-rated stocks.
What is Brainstorm Cell Therapeutics' stock price forecast for 2023?: 1 Wall Street research analysts have issued twelve-month price targets for Brainstorm Cell Therapeutics' shares. Their BCLI share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 226.8% from the stock's current price.
View analysts price targets for BCLI or view top-rated stocks among Wall Street analysts.
How have BCLI shares performed in 2022?: Brainstorm Cell Therapeutics' stock was trading at $4.00 on January 1st, 2022. Since then, BCLI stock has decreased by 61.8% and is now trading at $1.53.
View the best growth stocks for 2022 here.
When is Brainstorm Cell Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our BCLI earnings forecast.
How were Brainstorm Cell Therapeutics' earnings last quarter?: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) released its earnings results on Monday, November, 15th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.06. During the same period in the prior year, the business posted ($0.14) EPS.

What other stocks do shareholders of Brainstorm Cell Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Brainstorm Cell Therapeutics investors own include Organovo (ONVO), Gene Biotherapeutics (CRXM), Anavex Life Sciences (AVXL), Protalix BioTherapeutics (PLX), Sangamo Therapeutics (SGMO), Isoray (ISR), Mellanox Technologies (MLNX), Caladrius Biosciences (CLBS), Abeona Therapeutics (ABEO) and Adaptimmune Therapeutics (ADAP).
What is Brainstorm Cell Therapeutics' stock symbol?: Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."
Who are Brainstorm Cell Therapeutics' major shareholders?: Brainstorm Cell Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Abner Herrman & Brock LLC (0.77%), Raymond James & Associates (0.67%), Price T Rowe Associates Inc. MD (0.30%), Renaissance Technologies LLC (0.15%), TRU Independence Asset Management 2 LLC (0.12%) and Jmac Enterprises LLC (0.11%). Insiders that own company stock include David Setboun, International Holdings Ltd Acc, Preetam Shah, Ralph Dr Kern and Sankesh Abbhi.
View institutional ownership trends.
How do I buy shares of Brainstorm Cell Therapeutics?: Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Brainstorm Cell Therapeutics' stock price today?: One share of BCLI stock can currently be purchased for approximately $1.53.
How much money does Brainstorm Cell Therapeutics make?: Brainstorm Cell Therapeutics (NASDAQ:BCLI) has a market capitalization of $55.82 million. The biotechnology company earns $-24,460,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.
How can I contact Brainstorm Cell Therapeutics?: Brainstorm Cell Therapeutics' mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. The official website for the company is www.brainstorm-cell.com. The biotechnology company can be reached via phone at (201) 488-0460 or via email at pshah@brainstorm-cell.com.

This page (NASDAQ:BCLI) was last updated on 12/8/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial